The present invention relates to aptamers, polynucleotides, and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. Hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. Hyopneumoniae infection.

-Lactamase substrates and methods for using the substrates to detect -lactamase and to diagnose tuberculosis.

The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.

The purpose of the present invention is to provide a specific antibody applicable to immunochromatographic detection of Mycoplasma pneumoniae infections, and a detection reagent using the same, among others. Provided are a Mycoplasma pneumoniae detection reagent and kit that include a specific antibody against the P30 protein of Mycoplasma pneumoniae, and an immunochromatographic test device.

[Problem]

An object of the present invention is to provide a detection marker that can simply and rapidly detect Mycoplasma pneumoniae, which is a pathogen of mycoplasma pneumonia, at a high sensitivity, a specific antibody against the marker, and also an immunological detection method and a kit containing the antibody.

[Solution]

Infection with Mycoplasma pneumoniae can be rapidly and specifically diagnosed by producing an antibody specifically reactive to P30 protein of Mycoplasma pneumoniae and performing an immunological assay using the P30 protein as a detection marker. The present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the bacteria at a hospital or the like without need of specialized instruments or skilled techniques.

The present invention provides methods and compositions for detecting Mycoplasma exposure in a subject.

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

[Problem] An object of the present invention is to provide a detection marker that can simply and rapidly detect Mycoplasma pneumoniae, which is a pathogen of mycoplasma pneumonia, at a high sensitivity, a specific antibody against the marker, and also an immunological detection method and a kit containing the antibody. [Solution] Infection with Mycoplasma pneumoniae can be rapidly and specifically diagnosed by producing an antibody specifically reactive to P30 protein of Mycoplasma pneumoniae and performing an immunological assay using the P30 protein as a detection marker. The present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the bacteria at a hospital or the like without need of specialized instruments or skilled techniques.

Provided herein are compositions and methods for detection of detection and treatment of Mycoplasma haemofelis and Mycoplasma haemocanis.

The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.